DB
VIRX

Dmitry Balyasny’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Dmitry Balyasny’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-285,714
Closed -$36.9M – 2392
2017
Q4 		$36.9M Buy
+285,714
New +$26.8M 0.12% 232

Other funds holding VIRX

ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Dmitry Balyasny's VIRX Position: Q3 2019 in Review

Dmitry Balyasny sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2019, closing a stake of 47,691 shares — an estimated $1.21M sold.

Dmitry Balyasny first reported a position in VIRX in Q3 2014 and held it in 13 quarters. The position peaked at $8.12M in Q4 2017. 49 funds tracked by Wall St. Rank hold VIRX as of Q3 2019.

  • Dmitry Balyasny reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Dmitry Balyasny sold 47,691 Viracta Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $1.21M.
  • Dmitry Balyasny first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2014 and held it in 13 quarters.
  • Dmitry Balyasny's Viracta Therapeutics, Inc. Common Stock position peaked at $8.12M in Q4 2017.
  • 49 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Balyasny Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.